Chemotherapeutic targeting of p53.
Smith
Martin L
ML
Indiana University Cancer Center, Department of Microbiology, Indiana University School of Medicine, Indianapolis 46202, USA.
Fornace
Albert J
AJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D015195:Drug Design; D004357:Drug Synergism; D017353:Gene Deletion; D016158:Genes, p53; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000187:drug effects* / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy; D011487:Protein Conformation / Q000187:drug effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects* / Q000502:physiology
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin; C402665:CP 31398; D002945:Cisplatin